Published Date: 17 Feb 2023
BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...
Read Full NewsALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Why patients with IgA nephropathy want to understand their disease, not just follow instructions.
Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.
Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.
Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.
1.
Transperineal Biopsy IDs Active Surveillance Candidates
2.
Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?
3.
Breast Cancer Genetic Testing Need in Black Women Identified
4.
"We Caught It Early": Advantage or Disadvantage?
5.
After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.
1.
AI-Based Vision-Language Analysis of Histopathology: Transforming Diagnostic Pathology with Multimodal Deep Learning
2.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
3.
The Life-Saving Powers of Anemia: How to Combat the Disease.
4.
Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment
5.
Cancer in 2024: Global Trends, Challenges, and Innovations for Healthcare Professionals
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Cancer Care: From Awareness to Recovery
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation